Navigation Links
NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
Date:7/24/2009

SAN MATEO, Calif., July 24 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX) announced today the preliminary results of a short-term clinical study (Study C123) of Qutenza(TM) in patients with postherpetic neuralgia (PHN) following pretreatment with an FDA-approved topical anesthetic. As part of the ongoing new drug application (NDA) review, the U.S. Food and Drug Administration (FDA) requested the study to determine whether an FDA-approved topical anesthetic would provide similar tolerability to the topical agent used as a pretreatment in the clinical development program. The NDA for Qutenza in PHN has a Prescription Drug User Fee Act (PDUFA) date of August 16, 2009.

In Study C123, 24 patients received a single 60-minute Qutenza patch application following a 60-minute pretreatment with an FDA-approved topical anesthetic (2.5% lidocaine / 2.5% prilocaine). The mean duration of patch application was evaluated as the primary endpoint analysis. Patients were monitored for seven days following treatment.

Preliminary results of Study C123 showed the mean duration of patch application was 60.2 minutes, versus a target duration of Qutenza patch application of 60 minutes. No patients removed the Qutenza patch prematurely (i.e.< 90% of the intended full application time).

The company expects to provide results from Study C123 to the FDA prior to the PDUFA date of August 16, 2009. The impact on the agency's timing, if any, for an ultimate decision on the NDA is not yet known.

Dr. Jeffrey Tobias, NeurogesX' Chief Medical Officer commented, "I am grateful to our clinical investigators and the entire NeurogesX team for working together to quickly complete this study. We believe that these results will address the FDA's questions relating to the use of an FDA-approved to
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
2. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
3. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
4. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
5. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
6. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
7. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
8. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
9. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
10. Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results
11. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Minn. , Sept. 17, 2014  Rebiotix Inc. announced ... the company,s lead product candidate, RBX2660 (microbiota suspension) will be ... IDWeek 2014 conference in Philadelphia from ... be presented during the poster session on Thursday, October 9, ... C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD ...
(Date:9/17/2014)... , September 17, 2014 ... 17536, has shown positive data in a Phase 2a ... neuropathy , Glenmark Pharmaceuticals today ... Ankyrin 1 (TRPA1) antagonist, GRC 17536 has shown positive ... multi-centre, proof of concept study conducted on 138 patients ...
(Date:9/17/2014)... 2014  Members of the physician IT team ... announced today that the enterprise is working with ... sharing capabilities and provide immediate cluster fail over ... addition, the Dicom Systems enterprise imaging solutions will ... to more effectively deliver the right images to ...
Breaking Medicine Technology:PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3
... CARY, N.C., March 15, 2011 Saffron ... firm providing Natural Intelligence(1) solutions for business and ... leaders to its corporate Advisory Board . ... business-technology acumen, rich global business experience, and broad ...
... XTIO2 INC . (XTI) presented ... XTI ANTI-GERM / ANTI-VOC / ANTI-ALLERGY SYSTEM , consisting ...  Nano-Facemask . It is the world,s most effective preventive ... air and contact surfaces. The unique nanocoating protects people ...
Cached Medicine Technology:Saffron Technology Adds Seasoned Business Executives to Advisory Board 2Saffron Technology Adds Seasoned Business Executives to Advisory Board 3OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 2OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 3
(Date:9/17/2014)... September 17, 2014 Why are Asian Americans at ... Americans, and prone to develop the disease at lower ... in the transition from traditional high-fiber, low-fat Asian diets ... for those of Asian heritage, says George King, M.D., ... Diabetes Center and the senior author of the study. ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 Leading ... to announce the launch of its new vegan and ... is extremely effective and provided the results skincare testers ... to create a gentle yet active mask that provided ... Lake Louise.” , This Sugar Cane Fruit Mask combines ...
(Date:9/17/2014)... The Delta Dental Community Care Foundation announced today ... Health Foundation: America’s ToothFairy (NCOHF) to support oral health ... Zone Program® in California. , The Orange County NCOHF ... local constituent groups and stakeholders in a comprehensive approach ... its devastating effects on local families. The support of ...
(Date:9/17/2014)... 17, 2014 (HealthDay News) -- Managing diabetes, quitting smoking, ... weight can reduce the risk for dementia -- even ... The World Alzheimer Report 2014, commissioned by Alzheimer,s Disease ... dementia by 50 percent. The study noted that obesity ... diabetes as well as high blood pressure. ...
(Date:9/17/2014)... WASHINGTON -- The U.S. health care system is not ... the end of life and those of their families, ... a new report from the Institute of Medicine. ... approach to end-of-life care that integrates traditional medical care ... sustainable. The committee called for more "advance care ...
Breaking Medicine News(10 mins):Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2Health News:Delta Dental Community Care Foundation Donation to America's ToothFairy Helps Deliver Critical Services 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 3Health News:US health system not properly designed to meet needs of patients nearing end of life, says IOM 2Health News:US health system not properly designed to meet needs of patients nearing end of life, says IOM 3Health News:US health system not properly designed to meet needs of patients nearing end of life, says IOM 4Health News:US health system not properly designed to meet needs of patients nearing end of life, says IOM 5
... in Complex Rehab IndustryWILKES-BARRE, Pa., March 11 James ... years of experience, has joined Alliance Seating & ... accredited complex rehab companies. Conwell is an Assistive ... Supplier (CRTS) in Wilkes-Barre, Pa., for ASM ( www.alliance-seating.com ...
... Prevention, Treatment and Care Services for People around ... March 11 Late yesterday the ... Omnibus Appropriations bill for fiscal year 2009. ... last week, contains an appropriation of $900 million ...
... The U.S. Agency for International Development (USAID) ... launched a new program to reduce HIV vulnerability of ... The three-year, $5.1 million project is funded by the ... administered by USAID . A recent release study ...
... of cancer cells and their frequent divisions have their ... cells. Their metabolism runs at full speed and requires ... of iron in the cell lead to the production ... these, the cell inactivates free iron by binding it ...
... Amex: FHC ) today announced that it will ... of the FC2 Female Condom(R) on Thursday, March ... Company announced its receipt of FDA approval for the ... Shareholders and other interested parties may participate in the conference ...
... ROSEMONT, Ill., March 11 /PRNewswire-USNewswire/ -- Orthopaedic surgeon ... of Councilors (BOC) of the American Academy of ... the Venetian Sands Expo Center in Las Vegas. He ... "As Secretary, I will be one of the voices for ...
Cached Medicine News:Health News:Veteran Rehab Specialist, James Conwell, Joins Fast-Growing Alliance Seating & Mobility in Pennsylvania 2Health News:Congress Approves FY2009 Omnibus Appropriations Bill with $900 Million for The Global Fund 2Health News:USAID and IOM Announce HIV Prevention and Care for Farm Workers 2Health News:The Female Health Company Schedules Conference Call to Discuss FDA Approval of FC2 Female Condom(R) for March 12, 2009 2Health News:The Female Health Company Schedules Conference Call to Discuss FDA Approval of FC2 Female Condom(R) for March 12, 2009 3Health News:David Teuscher, MD, Elected Secretary of Academy Board of Councilors 2
5.5 pointed curved blade. Octagonal handle....
2 mm wide curved tip. Round handle....
3 mm disposable Lance blade. Can fit in to the N0521 Storz handle....
Consist of 6 disposable bevel blades (N0522) and chuck handle (0521). Malleable shafts. Designated most popular model or size....
Medicine Products: